



Sarri, G., Pedder, H., Dias, S., Guo, Y., & Lumsden, M. A. (2017). Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. *BJOG: An International Journal of Obstetrics and Gynaecology*, 124(10), 1514-1523. <https://doi.org/10.1111/1471-0528.14619>

Peer reviewed version

Link to published version (if available):
[10.1111/1471-0528.14619](https://doi.org/10.1111/1471-0528.14619)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Wiley at <http://onlinelibrary.wiley.com/doi/10.1111/1471-0528.14619/full>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

1 **Title: Vasomotor symptoms due to natural menopause; systematic review and network meta-**
2 **analysis (NMA) of treatment effects from the NICE Menopause Guideline**

3

4 Grammati Sarri¹, Hugo Pedder¹, Sofia Dias², Yelan Guo¹, and Mary Ann Lumsden³

5 Affiliations:

6 ¹ National Guideline Alliance, Royal College of Obstetricians and Gynaecologists, 27 Sussex Place,
7 Regent's Park, London, NW1 4RG, UK.

8 ² University of Bristol, School of Social and Community Medicine, Canynge Hall, 39 Whatley Road,
9 Bristol BS8 2PS, UK

10 ³ University of Glasgow, Chair of the Guideline Development Group

11 Correspondence: Hugo Pedder, hpedder@rcog.org.uk

12

13 **Running head:** Network meta-analysis of vasomotor symptoms in menopause

14

15

16

17 **Abstract**

18 **Background:** Vasomotor symptoms (VMS) are the hallmarks of menopause, occurring in
19 approximately 75% of postmenopausal women in the UK and are severe in 25%.

20 **Objectives:** To identify which treatments are most clinically effective for the relief of VMS for non-
21 hysterectomized women in natural menopause.

22 **Search Strategy:** English publications in MEDLINE, Embase and The Cochrane Library up to 13th
23 January 2015 were searched.

24 **Selection Criteria:** Randomized trials (RCTs) of treatments for women with a uterus for the
25 outcomes of frequency of VMS (up to 26 weeks), vaginal bleeding and discontinuation.

26 **Data Collection and Analysis:** Bayesian network meta-analysis (NMA) using mean ratios (MRs) and
27 odd ratios (ORs).

28 **Main Results:** Across the three networks, 47 RCTs of 16 treatment classes (N=8326 women) were
29 included. When compared to placebo, transdermal oestradiol and progestogen (O+P) had the
30 highest probability of being the most effective treatment for VMS relief (69.8%) (MR: 0.23 [95%CrI
31 (0.09, 0.57)]) whereas oral O+P was ranked lower than transdermal O+P, although oral and
32 transdermal O+P were no different for this outcome (MR: 2.23 [95%CrI (0.7, 7.1)]). Isoflavones and
33 black cohosh were more effective than placebo, though not significantly better than O+P. Not only
34 were SSRIs or SNRIs found ineffective in relieving VMS but they also had significantly higher odds of
35 discontinuation than placebo. Limited data were available for bleeding therefore no conclusions
36 could be made.

37 **Conclusions:** For non-hysterectomized women, transdermal O+P was the most effective treatment
38 for VMS relief.

39 **Keywords:** menopause, uterus, network meta-analysis, hormonal treatment.

40

41

42 **Tweetable abstract:** Which treatment best relieves menopause flushes? Results from the #NICE

43 guideline network meta-analysis

44

45 **Introduction**

46 Menopausal symptoms are extremely common. Vasomotor symptoms (VMS) comprising hot flushes
 47 and night sweats are the most common menopausal symptoms occurring in approximately 75% of
 48 postmenopausal women, with 25% of these being severely affected in the UK¹. The duration and
 49 severity of menopausal symptoms experienced are not uniform – symptoms may develop in the
 50 years before the final menstrual period and may persist for a few years or for many years in
 51 postmenopause.

52 Hot flushes often begin as the sudden sensation of heat centred on the upper chest and face. In
 53 some instances, this will become generalised, lasting for several minutes, and can be associated with
 54 profuse perspiration, palpitations or anxiety which may be very distressing and limit activities of
 55 daily living, particularly when they occur repeatedly during the day and at night. At night, hot flushes
 56 and night sweats will often cause insomnia that leads to fatigue. The mechanism of VMS appears to
 57 involve the central nervous system, possibly due to narrowing of the thermoregulatory-neutral zone
 58 in women with hot flushes, associated with instability of the skin blood vessels².

59 Different treatment options, pharmacological and non-pharmacological, have been used by women
 60 to relieve the VMS during menopause. Some of these treatments, such as hormone replacement
 61 therapy (HRT) target a “replacement” of oestrogen levels HRT comprises synthetic hormones
 62 including oestradiol, conjugated equine oestrogens, oestradiol valerate and several synthetic
 63 progestogens as well as tibolone which exhibits estrogenic, progestogenic and androgenic effects.
 64 Other treatments, such as herbal medicines and psychological therapies may work in different ways.
 65 As VMS may resolve naturally, some women simply do not wish to take hormones, while for others
 66 HRT is contraindicated, for example women who have (or are at high risk of) hormone-dependent
 67 cancer.

We aim to present the evidence obtained via a systematic review (SR), using network meta-analysis (NMA), of pharmacological and non-pharmacological treatments for the relief of VMS, relief of adverse events (such as vaginal bleeding) and discontinuation. This NMA formed part of the evidence underpinned the development of National Institute of Health and Care Excellence (NICE) Menopause Guideline (NG23) (<https://www.nice.org.uk/guidance/ng23>)³. The use of NMA is recommended in healthcare decision making when multiple treatments are considered for one indication and these treatments have not been directly compared in the same trials.

Methods

Systematic Reviews

The protocol of the SR was agreed by the Guideline Development Group (GDG) (Appendix S1), was conducted as part of the development of NICE guideline on menopause (NG23) <https://www.nice.org.uk/guidance/ng23> and is reported according to the PRISMA extension statement for systematic reviews incorporating NMAs of health care interventions⁴. A cost-effectiveness model using results from this NMA, in addition to other evidence, were used by the GDG to make recommendations in the guideline. In summary, the SRs included only randomised controlled trials (RCTs) that assessed pharmacological and/or non-pharmacological treatments for reducing the frequency of VMS, treatment discontinuation and vaginal bleeding for women aged 45 years or older with a diagnosis of natural menopause (defined as amenorrhea for at least 12 consecutive months).

The population in the NMA protocol was stratified into three groups that formed three networks of connected treatments: women with a uterus, women without a uterus, women with a history or at risk of breast cancer. This paper presents the results of the first network (women with a uterus). For non-oestrogenic treatments we included studies of women without a uterus as their effect was found to be clinically similar. For studies investigating oestrogen plus progestogen we included

92 mixed studies of women with a uterus and without a uterus as long as more than two thirds (66.6%)
93 of the study sample were women with a uterus (Appendix S1).

94 The efficacy endpoint was the frequency of VMS at the end of treatment, whereas vaginal bleeding
95 and treatment discontinuation were considered measures of adverse events. Although distress
96 caused by VMS may have been an equal relevant outcome for women in menopause, the frequency
97 of VMS was the most commonly reported outcome in studies, and the Guideline Committee
98 highlighted that VMS were highly prevalent among women seeking treatment for menopausal
99 symptoms. Vaginal bleeding and treatment discontinuation were prioritised due to their importance
100 on continuity of healthcare, costs of further treatment, and long-term impact. .

101 The time points of outcomes recorded were guided by clinical decision on the minimum duration of
102 a trial for the intervention to be effective. Non-hormonal treatments were considered by the GDG
103 to take a minimum of four weeks to be effective, whilst hormonal treatments were considered to
104 take longer (12 weeks). As shorter-term outcomes were the focus of this review, 26 weeks was
105 considered to be the maximum follow-up time we would include, to avoid long-term changes in
106 treatment efficacy that might cause heterogeneity within the network.

107 All searches were conducted in MEDLINE Embase and The Cochrane Library up to 13th January 2015
108 restricted to English written articles according to the parameters stipulated within the NICE
109 Guidelines Manual 2015 (<https://www.nice.org.uk/article/PMG20/chapter/4-Developing-review-questions-and-planning-the-evidence-review>) (Appendix S2),. Literature reviews, posters, letters,
110 editorials, comment articles, unpublished studies and studies not in English were excluded. Full
111 search strategies were published as part of the full NICE guideline
112 (<http://www.nice.org.uk/guidance/ng23/evidence/appendices-ag-559549262>).

114 Search strategies were quality assured by cross-checking reference lists of highly relevant papers and
115 comparing with search strategies in other SRs.

116 *Data extraction*

117 Data were double extracted in a structured form using a guide developed by the authors for Data
 118 Extraction for Complex Meta-anALysis (DECiMAL) independently by two reviewers⁵⁵. Discrepancies
 119 in data extraction were addressed by a senior reviewer who resolved any conflicts.

120 The quality of the studies was evaluated using two domains (risk of bias, indirectness) of the
 121 ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’
 122 developed by the international GRADE working group (<http://www.gradeworkinggroup.org/>)⁶.
 123 Detailed results for risk of bias domains are shown in Table S2.

124 *Statistical models*

125 NMA was formulated to synthesise direct and indirect evidence of treatments’ effects to reduce the
 126 frequency of VMS, treatment discontinuation and vaginal bleeding using the software WinBUGS
 127 version 1.4.3. We used statistical models for both fixed and random effects that allowed inclusion of
 128 multi-arm trials and accounted for the correlation between arms in the trials with any number of
 129 trial arms⁷. A class effect model was selected for the NMA with the underlying assumption that the
 130 effectiveness of different treatments under the same class would be comparable. This decision was
 131 made to maximise the availability of data and borrow strength from different trials. Data were
 132 available on dosing for many treatments, but the sparseness of the networks meant that it was
 133 necessary to borrow strength on dosing within treatments by assuming different doses of the same
 134 treatment had the same class effects (fixed effects model (FE)). A model allowing for within-class
 135 variability was also assessed to check if it improved model fit and reduced heterogeneity (random
 136 effects model (RE)). Two RE models for this were explored: an exchangeable dose effects model,
 137 where the pooled relative effects of different treatment doses were assumed to be randomly
 138 distributed within each treatment with a common variance (requiring modelling using a second
 139 variance parameter); and a fixed dose effects model, where the pooled relative dose effects are
 140 assumed equal for all doses of a treatment. For treatments where dosing information was not

available, the relative effect at the dose level was assumed to be equal to the treatment effect in both models.

WinBUGS code was adapted from the Dias et al 2011 and is available from the NICE appendices (<https://www.nice.org.uk/guidance/ng23/evidence/appendices-ik-559549264>). The following prior distributions were used:

- Log mean ratios (MRs) in the comparator arms for each study were normally distributed with mean of zero and variance of 1000
- Pooled log MRs at the treatment or class level (depending on model used) were normally distributed with mean of zero and variance of 1000
- Between-study standard deviation followed a uniform distribution between zero and two
- Within-class standard deviation followed a uniform distribution between zero and two

Placebo was selected as the baseline comparator for all networks as it was the treatment arm most commonly evaluated in RCTs. As no dependency on time was identified in exploratory analyses, discontinuation of treatment and vaginal bleeding were treated as dichotomous outcomes and were modelled on the log-odds ratio scale (Figure S2). Exploratory analyses also showed that baseline frequency of VMS followed an overdispersed Poisson distribution thus it was not appropriate to use a standard Poisson distribution to model the frequency of VMS (Figure S3). The negative binomial distribution can be used to model an overdispersed Poisson distribution, by including a parameter that accounts for the overdispersion^{8,9,10}. The mean of this negative binomial is interpreted as the rate of the over-dispersed Poisson and can be approximated by a normal distribution. We therefore model the mean using a log link function and relative treatment effects are estimated as log-mean ratios. Our motivation was to model data as closely as possible to the mechanism by which they were generated (i.e. from an overdispersed Poisson distribution) and this approximation provided a

simple computational solution whilst retaining the interpretation of the pooled effect as mean rates of VMS

On the log mean ratio scale, final and change from baseline frequencies of VMS could not be pooled, so the latter was transformed so that all effects could be modelled as final frequencies. A correlation coefficient of 0.55 was used to estimate final frequencies from change from baseline. This was calculated from two included studies which reported baseline, final and change from baseline results in full^{11,12}.

All three models (FE, RE with fixed dose effects, RE with exchangeable dose effects) were compared based on residual deviance and deviance information criteria (DIC)^{7,13}. Between-studies heterogeneity estimates from random effects models are presented as median and 95% credible intervals (95%CrI).

Inconsistency in the networks was tested in closed loops of treatment comparisons by node-splitting¹⁴. This technique allows the splitting of direct and indirect information contributing to each treatment effect. The difference between these contributions can be statistically tested, with a rejection of the null hypothesis indicating significant inconsistency in the network.

The output of the NMA was expressed as the probability of each treatment being the best for an outcome (based on the proportion of Markov chain simulations in which a treatment ranked first) and the ranking of treatments (presented as median rank and its 95%CrI). The estimation of summary estimates (mean ratios [MRs] or odds ratios [ORs]) were also calculated for comparisons of the direct and indirect evidence using medians and 95%CrIs from the posterior distributions.

Two types of sensitivity analyses were predefined in the NMA protocol. The first focused on changing the value of the correlation coefficient used to estimate final frequencies of VMS from change from baseline, from 0.55 in the original analysis to a typically assumed correlation between baseline and follow-up of 0.75. The second analysis tested if differences in treatment efficacy could

be explained by differences in dosing. Studies investigating the treatment of low dose oral oestradiol plus progestogen were removed from the analysis to determine if this dose was reducing the overall efficacy of oral oestradiol plus progestogen in the model. The final results were not found to be sensitive to either of these changes.

A further post-hoc sensitivity analysis was considered to investigate the effect of including mixed population studies (women with and without a uterus) of oestrogen plus progestogen. However, as there was only a single study³² that included mixed populations for this treatment comparison, exclusion of the study removed oestrogen plus progestogen oral from the network and prevented estimation of the efficacy of this treatment. No other results were affected by the exclusion of this study.

Results

47 RCTs matched the protocol, presented information for at least one of the outcomes and were included in the NMA (Figure S1). For the two first networks (frequency of VMS and discontinuation of treatment), DIC suggested that there was a small difference between any of the models (differences less than 5 points are not considered meaningful) (Tables S7). However, the residual deviance for the random effects model with fixed dose effects for both these networks was slightly closer to the number of unconstrained data points than either of the other models (for the fixed effects and random effects with exchangeable dose effects respectively). Therefore, the results of the random effects model with fixed dose effects are presented for these two networks. For the network of vaginal bleeding, the results of the fixed effects model are presented, as the estimate of heterogeneity for the random effects model was unstable, and strongly influenced by the prior distribution.

a. Reducing the frequency of VMS

A total of 32 RCTs of 12 treatment classes (placebo, sham acupuncture, oestrogen plus progestogen non-oral, oestrogen plus progestogen oral, tibolone, raloxifene, SSRIs/SNRIs, isoflavones, Chinese herbal medicine, black cohosh, multibotanicals, acupuncture) with a sample size of 4165 women were included for the NMA for VMS (Figure 1, Table S1). Two included RCTs was at very high risk of bias and 13 were high risk (Table S2). The other 21 RCTs were low or moderate risk. The combination of oestrogen plus progestogen via patches was found to be better than placebo (MR 0.23 95%CrI (0.09, 0.57)) at relieving VMS for women in menopause and had the highest probability of being the best treatment (68.9%) (Figure 2A, Table 1). Although, the 95%CrI for combination of oral oestrogen plus progesterone compared to placebo was wide (MR 0.52 (0.25, 1.06)), the point estimate suggested that it may have good efficacy, similar to that of transdermal oestrogen plus progestogen. In addition, there was strong evidence to suggest that the combination of oestrogen plus progestogen via patches was more effective than raloxifene, SSRIs/SNRIs, isoflavones and Chinese herbal medicine in relieving VMS. Isoflavones and black cohosh were also found to be better than placebo. There was no strong evidence of any other effects among other interventions in the network (Table S3).

High heterogeneity was found between studies, reducing the precision of estimates. This is likely to have arisen because of the clinical differences in patients included in the studies – the baseline frequency of hot flushes varied considerably between studies. Inconsistency was assessed in the closed loop between placebo, sham acupuncture and acupuncture, but no difference was found between results obtained through direct and indirect evidence (Table S3).

a. Treatment discontinuation

A total of 21 RCTs of 10 treatment classes (placebo, oestrogen plus progestogen oral, conjugated oestrogens plus bazedoxifene, tibolone, SSRIs/SNRIs, gabapentin, isoflavones, Chinese herbal medicine, multibotanicals, valerian root) with a sample size of 4829 women were included in the

network for discontinuation of treatment (Figure 1, Table S1). Because of high heterogeneity between the studies included in the NMA, uncertainty of the results was increased. Inconsistency could not be assessed in this network as there were no closed-treatment loops. Only 4 RCTs were at high risk of bias. The other 17 were low or moderate risk (Table S2). There was evidence that the combination of non-oral oestrogen plus progestogen had significantly lower odds of discontinuation than than placebo (OR 0.61 95%CrI (0.37, 0.99)). In addition, there was evidence that conjugated oestrogens plus bazedoxifene (OR 0.31 95%CrI (0.1, 1.00)) was more effective than placebo in this outcome, although there was considerable uncertainty in this result. There was strong evidence that SSRIs/SNRIs were worse than placebo (OR 1.66 95%CrI (1.07, 2.61)) on discontinuation of treatment. There was evidence that Tibolone and SSRIs/SNRIs were worse than non-oral oestrogen plus progestogen and conjugated oestrogens plus bazedoxifene for this outcome (Figure 2B, Table 2, Table S4).

In this analysis, conjugated oestrogens plus bazedoxifene and valerian root were found to have the highest probability (37.34% and 37% respectively) of being the best treatments in relation to discontinuation of treatment among interventions with duration up to 26 weeks, although note that these probabilities are small and below 50%

a. Vaginal bleeding

The network of vaginal bleeding included five RCTs of 5 treatment classes (placebo, oestrogen plus progestogen oral, tibolone, SSRIs/SNRIs, gabapentin) (Figure 1, Table S1) with a sample size of 1367 women. Neither heterogeneity nor inconsistency could be assessed in the network due to its sparseness. A fixed effects model was used and there were no closed-treatment loops. One study was at high risk of bias, one was low risk, and the other three were moderate risk (Table S2). The sparseness of data within the network meant that there was a high degree of uncertainty in estimates, and no conclusions could be drawn regarding effects of treatments on vaginal bleeding (adverse event) (Figure 2C, Table S5, Table S6).

262

263 **Discussion**

264 This paper summarizes the evidence included in three SRs and analysed in NMAs for the outcomes
265 of relief of frequency of VMS, treatment discontinuation and vaginal bleeding among
266 pharmacological and non-pharmacological treatments for women with a uterus who have
267 undergone a natural menopause. To our knowledge, this is the first publication using this type of
268 complex analysis in the research field of menopause.

269 *Main findings*

270 NMA results showed that for women with a uterus, the oestrogen plus progestogen transdermal
271 patch was the most effective treatment to relieve the frequency of VMS, with a lower odds of
272 discontinuation compared with all the other available treatments (hormonal, non-hormonal and
273 non-pharmacological). There was evidence that oestrogen plus progestogen taken orally may be
274 more effective to relieve VMS than placebo, but this did not rank as highly as transdermal oestrogen
275 plus progestogen in the hierarchy of the best treatment options for this outcome. However, in the
276 clinical setting both may be considered as options, depending on the individual's response to
277 treatment. Although isoflavones and black cohosh, were also shown to be more effective than
278 placebo in relief of VMS for women with a uterus, there was no evidence that their efficacy differed
279 from combined oestrogen plus progestogen. However, these results should be interpreted with
280 caution as there was a variety of herbal preparations used in different studies. SSRIs/SNRIs were not
281 found to be effective in relieving VMS but were found to have higher odds of discontinuation
282 compared to the other treatments, as would be expected due to the serious side effects profile of
283 these treatments. However, the NMA demonstrated that women treated with non-oral oestradiol
284 plus progestogen or with conjugated oestrogens plus bazedoxifene were less likely to discontinue
285 treatment than if they were treated with placebo or tibolone.

No conclusive points could be made for the outcome of vaginal bleeding for women with a uterus given the limited data for this outcome and the lack of inclusion of several interventions in the network.

During the NICE guideline development, results of clinical efficacy from the NMA were incorporated into a probabilistic cost-effectiveness analysis that informed the decision-making of the Guideline Committee. The Committee concluded that women with a uterus should be offered the treatment of oestrogen and progestogen (HRT) for the relief of VMS, following an individualized approach and after discussing with them the short-term (up to 5 years) and longer-term benefits and risks. Health professionals should not routinely offer selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs) or clonidine as first-line treatment for VMS alone and should explain to women that although there is some evidence that isoflavones or black cohosh may relieve VMS there are health concerns in relation to safety of multiple preparations and interactions with other medicines (<https://www.nice.org.uk/guidance/ng23/>)

Strengths and Limitations

This is the first NMA designed to include simultaneous comparison of randomized evidence aiming to reduce the frequency of VMS for women in menopause. Advanced statistical techniques were employed to make best use of available evidence. A novel NMA model which accounts for the nature of the VMS data, distributed as overdispersed Poisson, and incorporates class effects and transformation of change from baseline scores of outcomes, was developed to make use of as much relevant and available data as possible. We were therefore simultaneously able to compare several interventions of interest to women and policy makers that had not been compared previously in head-to-head trials.

Overall there were relatively few studies included in the networks compared to the number of treatment comparisons. This may have led to the within-class standard deviation parameter not being fully informed, which could explain the better fit of the fixed dose effect RE model compared

to the exchangeable dose effect RE model. A dose-response relationship might have been expected in the data, but as the protocol specified that treatments had to be administered within selective doses specified in the British National Formulary, the range of doses was often very small. Furthermore, body weights and absorption can vary substantially between patients, and this is likely to lead to as much (if not more) variation in bioavailability of treatment than the administered dose.

Several decisions were made at the protocol stage that impacted the selection of data included in the networks and therefore the representativeness of all available evidence in this area. For example, we included only English-published studies, which may have limited our evidence on some treatments (e.g. Chinese herbal medicines), and publication bias was not easily assessed.

Furthermore, it was decided to examine the role of different treatments used to reduce the frequency rather than the severity of VMS, which resulted in some treatments such as cognitive behaviour therapy being excluded from the NMA. The selection of outcomes for inclusion in the NMA was based on both their clinical importance and relevance to women in menopause. Frequency of VMS, discontinuation and vaginal bleeding were prioritised for inclusion due to their high prevalence and availability of evidence.

Assumptions were also made for the minimum duration of trials for inclusion in the NMA and the minimum acceptable criteria for mixed population studies. These assumptions are commonly made when a complex meta-analysis is designed and aim to increase the homogeneity and validity of included data. However, this resulted in a number of studies being excluded from further analysis. Some studies were also excluded because the data reported did not give an indication of variability (no information on standard deviation or standard error of results). For the small minority of studies that were excluded because they did not connect to the network, their results and whether they would influence decision-making were further discussed with the GDG. This information was used as supplementary evidence to facilitate the Group's discussion which recognised the importance of these treatments in the management of some women with menopause, especially if they do not

336 wish to be treated with pharmacological treatments (such as HRT) and these options were
337 highlighted in terms of provision of general advice and information.

338 *Interpretation*

339 This is the first NMA designed to include simultaneous comparison of randomized evidence from
340 pharmacological and non-pharmacological treatments aiming to reduce the frequency of VMS for
341 women in menopause. After taking into account the assumptions used for this NMA and the
342 limitations of this approach, these results provided a comprehensive framework for decision making
343 by combining direct and indirect evidence on treatments for the relief of VMS in menopause. Our
344 reviewed literature did not identify any other similar type of analysis that could be used for our
345 results comparison.

346

347 **Conclusions**

348 There is evidence that transdermal oestradiol plus progestogen greatly reduces the frequency of hot
349 flushes in women with a uterus. Although there is some evidence of efficacy of oral oestrogen plus
350 progestogen treatment, the health economic analysis and the GDG's expert opinion supported the
351 use of both types of oestradiol plus progestogen's administration in clinical practice.

352 **Acknowledgements**

353 The authors thank Nichole Taske (NICE Director for Methodology) for providing valuable comments
354 on earlier versions of this paper.

355 **Disclosure of interests**

356 We declare the following interests based on NICE's policy on conflicts of interests (available at:
357 [www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/code-of-practicefor-](http://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/code-of-practicefor-declaring-and-managing-conflicts-of-interest.pdf)
358 [declaring-and-managing-conflicts-of-interest.pdf](http://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/code-of-practicefor-declaring-and-managing-conflicts-of-interest.pdf)). MAL has been remunerated for chairing NICE
359 guideline development committees and is vice chair of the Women's Health Expert Advisory Group
360 to the Medicines and Healthcare products Regulatory Agency (MHRA). SD is co-investigator on an
361 MRC/Pfizer collaboration grant in which Pfizer part-fund a researcher (not SD). GS, HP and YG have
362 no conflicts of interest to declare. ICMJE disclosure forms are available as online supporting
363 information.

364 **Contributions to authorship**

365 GS has prepared the first draft of the publication and was responsible for revisions and ensuring
366 overall integrity of the process. All co-authors (GS, HP, YG, SD, MAL) contributed to reviews and
367 approved the final version of the manuscript.

368 **Funding**

369 This work was undertaken in part by authors (GS, HP, YG) from the National Guideline Alliance
370 (formerly the National Collaborating Centre for Women and Children's Health) which received
371 funding from the National Institute for Health and Care Excellence. The views expressed in this
372 publication are those of the authors and not necessarily those of the Institute.

373 SD received support from the Centre for Clinical Practice (NICE), with funding from the NICE Clinical
374 Guidelines Technical Support Unit, University of Bristol and from the Medical Research Council (MRC
375 Grant MR/M005232/1)

References

1. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition. *JAMA Intern Med* 2015; 175:531-9.
2. Sassarini J, Fox H, Ferrell W, Sattar N, Lumsden MA. Hot flushes, vascular reactivity and the role of the adrenergic nervous system. *Climacteric Aug* 2012; 15:332-8.
3. National Institute for Health and Care Excellence. Menopause: diagnosis and management (Clinical guideline23) 2015. <https://www.nice.org.uk/guidance/ng23>.
4. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015; 162:777-84.
5. Pedder HP, Sarri G, Keeney E, Nunes V, Dias S. Data Extraction for Complex Meta-Analysis (DECIMAL) Guide. *Syst Rev* 2016; 5:212.
6. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336:924-6
7. Dias S, Sutton AJ, Ades AE, Welton NJ Evidence Synthesis for Decision Making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. *Med Decis Making* 2013; 33:607-17.
8. McCullagh P, Nelder JA. *Generalised Linear Models 2nd edition*. London: Chapman and Hall, 1989.
9. Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter D. *The BUGS book*. Boca Raton: Talor & Francis Inc, 2013.

- 400 10. Martina R, Kay R, van Maanen R, Ridder A. The analysis of incontinence episodes and other
 401 count data in patients with overactive bladder by Poisson and negative binomial regression.
 402 *Pharm Stat* 2014; 14:151-60.
- 403 11. Faure ED, Chantre P, Mares P. Effects of a standardised soy extract on hot flushes: a
 404 multicenter, double-blind, randomized, placebo-controlled study. *Menopause* 2002; 9:329-
 405 34.
- 406 12. Lin SQ, Sun LZ, Lin JF, Yang X, Zhang LJ, Qiao J, et al. Estradiol 1 mg and drospirenone 2 mg as
 407 hormone replacement therapy in postmenopausal Chinese women. *Climacteric* 2011;
 408 14:472-81.
- 409 13. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model
 410 complexity and fit. *J R Stat Soc Series B Stat Methodol* 2002; 64:583-616.
- 411 14. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment
 412 comparison meta-analysis. *Stat Med* 2010; 29:932-44.
- 413 15. Al-Azzawi F, Wahab M, Habiba M, Akkad A, Mason T. Continuous combined hormone
 414 replacement therapy compared with tibolone. *Obstet and Gynecol* 1999; 93:258-64.
- 415 16. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary
 416 soy supplementation on hot flushes. *Obstet Gynecol* 1998; 91:6-11.
- 417 17. Baber RJ, Templeman C, Morton T, Kelly GE, West L. Randomized placebo-controlled trial of
 418 an isoflavone supplement and menopausal symptoms in women. *Climacteric* 1999; 2:85-92.
- 419 18. Burke GL, Legault C, Anthony M, Bland DR, Morgan TM, Naughton MJ, et al. Soy protein and
 420 isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy
 421 Estrogen Alternative Study. *Menopause* 2003; 10:147-53.
- 422 19. D'Anna R, Cannata ML, Marini H, Atteritano M, Cancellieri F, Corrado F, et al. Effects of the
 423 phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in
 424 postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study.
 425 *Menopause* 2009; 16:301-6.

- 426 20. Endrikat J, Graeser T, Mellinger U, Ertan K, Holz C. A multicenter, prospective, randomized,
427 double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined
428 hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot
429 flushes in postmenopausal women. *Maturitas* 2007; 58:201-7.
- 430 21. Evans M, Elliott JG, Sharma P, Berman R, Guthrie N. The effect of synthetic genistein on
431 menopause symptom management in healthy postmenopausal women: a multi-center,
432 randomized, placebo-controlled study. *Maturitas* 2011; 68:189-96.
- 433 22. Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a
434 multicenter, double-blind, randomized, placebo-controlled study. *Menopause* 2002; 9:329-
435 34.
- 436 23. Ferrari A. Soy extract phytoestrogens with high dose of isoflavones for menopausal
437 symptoms. *J Obstet Gynaecol Res* 2009; 35:1083-90.
- 438 24. Freedman RR. Treatment of menopausal hot flashes with 5-hydroxytryptophan. *Maturitas*
439 2010; 65:383-5.
- 440 25. Freedman RR, Kruger ML, Tancer ME. Escitalopram treatment of menopausal hot flashes.
441 *Menopause* 2011; 18:893-96.
- 442 26. Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H, et al. Efficacy of
443 escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.
444 *JAMA* 2011; 305: 267-74.
- 445 27. Garcia JT, Gonzaga F, Tan D, Ng TY, Oei PL, Chan CW. Use of a multibotanical (Nutrafem) for
446 the relief of menopausal vasomotor symptoms: a double-blind, placebo-controlled study.
447 *Menopause* 2010; 17:303-8.
- 448 28. Gordon PR, Kerwin JP, Boesen KG, Senf J. Sertraline to treat hot flashes: a randomized
449 controlled, double-blind, crossover trial in a general population. *Menopause* 2006; 13:568-
450 75.

29. Grady D, Cohen B, Tice J, Kristof M, Olyaie A, Sawaya GF. Ineffectiveness of sertraline for treatment of menopausal hot flashes: a randomized controlled trial. *Obstet Gynecol* 2007; 109:823-30.
30. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. *Obstet Gynecol* 2003; 101:337-45.
31. Hachul H, Brandão LC, D'Almeida V, Bittencourt LR, Baracat EC, Tufik S. Isoflavones decrease insomnia in postmenopause. *Menopause* 2011; 18:178-84.
32. Hammar ML, van de Weijer P, Franke HR, Pornel B, von Mauw EM, Nijland EA. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. *BJOG* 2007; 114:1522-9.
33. Joffe H, Guthrie KA, LaCroix AZ, Reed SD, Ensrud KE, Manson JE, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. *JAMA Intern Med* 2014; 174:1058-66.
34. Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. *Breast J* 2006; 12:114-22.
35. Knight DC, Howes JB, Eden JA. The effect of Promensil, an isoflavone extract, on menopausal symptoms. *Climacteric* 1999; 2:79-84.
36. Knight DC, Howes JB, Eden JA, Howes LG. Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation. *Climacteric* 2001; 4:13-8.
37. Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flashes and sweats per day. *Maturitas* 2005; 50:222-30.
38. Lin SQ, Sun LZ, Lin JF, Yang X, Zhang LJ, Qiao J, et al. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women. *Climacteric* 2011; 14:472-81.


- 477 39. Lipovac M, Chedraui P, Gruenhut C, Gocan A, Kurz C, Neuber B, et al. The effect of red clover
478 isoflavone supplementation over vasomotor and menopausal symptoms in postmenopausal
479 women. *Gynecol Endocrinol* 2012; 28:203-7.
- 480 40. Mirabi P, Mojab F. The effects of valerian root on hot flashes in menopausal women. *Iran J*
481 *Pharm Res* 2013; 12:217-22.
- 482 41. Nedeljkovic M, Tian L, Ji P, Déglon-Fischer A, Stute P, Ocon E, et al. Effects of acupuncture
483 and Chinese herbal medicine (Zhi Mu 14) on hot flushes and quality of life in
484 postmenopausal women: results of a four-arm randomized controlled pilot trial. *Menopause*
485 2014; 21:15-24.
- 486 42. Nir Y, Huang MI, Schnyer R, Chen B, Manber R. Acupuncture for postmenopausal hot flashes.
487 *Maturitas* 2007; 56:383-95.
- 488 43. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-
489 estradiol dose for treating vasomotor symptoms. *Obstet Gynecol* 2000; 95:726-31.
- 490 44. Palacios S, Farias ML, Luebbert H, Gomez G, Yabur JA, Quail DC, et al. Raloxifene is not
491 associated with biologically relevant changes in hot flushes in postmenopausal women for
492 whom therapy is appropriate. *Am J Obstet Gynecol* 2004; 191:121-31.
- 493 45. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone
494 acetate: effective menopausal symptom relief. *Climacteric* 2007; 10:120-31.
- 495 46. Penotti,M., Fabio,E., Modena,A.B., Rinaldi,M., Omodei,U., Viganò,P. (2003) Effect of soy-
496 derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the
497 uterine and cerebral arteries, *Fertility and Sterility*, 79: 1112-1117.
- 498 47. Penotti M, Fabio E, Modena AB, Rinaldi M, Omodei U, Viganó P. Effect of soy-derived
499 isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine
500 and cerebral arteries. *Fertil Steril* 2003; 79:1112-7.

- 501 48. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms
502 with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a
503 randomized, controlled trial. *Menopause* 2009; 16:1116-24
- 504 49. Pinkerton JV, Constantine G, Hwang E, Cheng RF; Study 3353 Investigators. Desvenlafaxine
505 compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week,
506 multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
507 *Menopause* 2013; 20:28-37.
- 508 50. Pinkerton JV, Kagan R, Portman D, Sathyanarayana R, Sweeney M; Breeze 3 Investigators.
509 Phase 3 randomized controlled study of gastroretentive gabapentin for the treatment of
510 moderate-to-severe hot flashes in menopause. *Menopause* 2014; 21:567-73.
- 511 51. Rotem,C., Kaplan,B. (2007) Phyto-Female Complex for the relief of hot flushes, night sweats
512 and quality of sleep: randomized, controlled, double-blind pilot study, *Gynecological*
513 *Endocrinology*, 23: 117-122.
- 514 52. Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flushes, night sweats and
515 quality of sleep: randomized, controlled, double-blind pilot study. *Gynecol Endocrinol* 2007;
516 23:117-22.
- 517 53. Schurmann,R., Holler,T., Benda,N. (2004) Estradiol and drospirenone for climacteric
518 symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled
519 study of the safety and efficacy of three dose regimens, *Climacteric*, 7: 189-196.
- 520 54. Schürmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in
521 postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety
522 and efficacy of three dose regimens. *Climacteric* 2004; 7:189-96.
- 523 55. Shahnazi M, Nahae J, Mohammad-Alizadeh-Charandabi S, Bayatipayan S. Effect of black
524 cohosh (*cimicifuga racemosa*) on vasomotor symptoms in postmenopausal women: a
525 randomized clinical trial. *J Caring Sci* 2013; 2:105-13.


- 526 56. Speroff,L., Whitcomb,R.W., Kempfert,N.J., Boyd,R.A., Paulissen,J.B., Rowan,J.P. (1996)
527 Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the
528 treatment of menopausal vasomotor symptoms, *Obstetrics and Gynecology*, 88: 587-592,
- 529 57. Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local
530 tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of
531 menopausal vasomotor symptoms. *Obstet Gynecol* 1996; 88:587-92.
- 532 58. Stearns,V., Beebe,K.L., Iyengar,M., Dube,E. (2003) Paroxetine controlled release in the
533 treatment of menopausal hot flashes: a randomized controlled trial, *JAMA*, 289: 2827-2834.
- 534 59. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of
535 menopausal hot flashes: a randomized controlled trial. *JAMA* 2003; 289:2827-34.
- 536 60. Stevenson JC, Durand G, Kahler E, Pertyński T. Oral ultra-low dose continuous combined
537 hormone replacement therapy with 0.5 mg 17 β -oestradiol and 2.5 mg dydrogesterone for
538 the treatment of vasomotor symptoms: results from a double-blind, controlled study.
539 *Maturitas* 2010; 67:227-32.
- 540 61. van de Weijer PH, Barentsen R. Isoflavones from red clover (Promensil) significantly reduce
541 menopausal hot flush symptoms compared with placebo. *Maturitas* 2002; 42:187-93.
- 542 62. Verhoeven MO, van der Mooren MJ, van de Weijer PH, Verdegem PJ, van der Burgt LM,
543 Kenemans P, et al. Effect of a combination of isoflavones and *Actaea racemosa* Linnaeus on
544 climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week
545 randomized, placebo-controlled, double-blind study. *Menopause* 2005; 12:412-20.
- 546 63. Wyon Y, Wijma K, Nedstrand E, Hammar M. A comparison of acupuncture and oral estradiol
547 treatment of vasomotor symptoms in postmenopausal women. *Climacteric* 2004; 7:153-64.
- 548 64. Xia Y, Zhao Y, Ren M, Zhang J, Wang Y, Chang Y, et al. A randomized double-blind placebo-
549 controlled trial of a Chinese herbal medicine preparation (Jiawei Qing'e Fang) for hot flashes
550 and quality of life in perimenopausal women. *Menopause* 2012; 19:234-44.

- 551 65. Zaborowska,E., Brynhildsen,J., Damberg,S., Fredriksson,M., Lindh-Astrand,L., Nedstrand,E.,
552 Wyon,Y., Hammar,M. (2007) Effects of acupuncture, applied relaxation, estrogens and
553 placebo on hot flushes in postmenopausal women: an analysis of two prospective, parallel,
554 randomized studies, *Climacteric*, 10: 38-45.
- 555 66. Zaborowska E, Brynhildsen J, Damberg S, Fredriksson M, Lindh-Astrand L, Nedstrand E, et al.
556 Effects of acupuncture, applied relaxation, estrogens and placebo on hot flushes in
557 postmenopausal women: an analysis of two prospective, parallel, randomized studies.
558 *Climacteric* 2007; 10:38-45.
- 559 67. Zhong LL, Tong Y, Tang GW, Zhang ZJ, Choi WK, Cheng KL, et al. A randomized, double-blind,
560 controlled trial of a Chinese herbal formula (Er-Xian decoction) for menopausal symptoms in
561 Hong Kong perimenopausal women. *Menopause* 2013; 20:767-76.


VMS - Women with a uterus



Discontinuation - Women with a uterus



Vaginal Bleeding - Women with a uterus








Table 1: Log mean ratios (with their 95% CI) of all interventions in the network and the probability of being the best treatment for reducing the frequency of VMS

	Median log mean ratios	95%CrI	Probability of being the best treatment	Median (95% CrI) treatment rank
Placebo	<i>Reference treatment</i>		0.00%	10 (7-12)
Sham acupuncture	-0.30	(-1.32, 0.64)	1.44%	7 (2-12)
Oestrogen + progestogen non-oral	-1.46	(-2.37, -0.56)	69.82%	1 (1-5)
Oestrogen + progestogen oral	-0.67	(-1.4, 0.06)	3.73%	4 (1-10)
Tibolone	-0.60	(-1.45, 0.25)	4.02%	5 (1-11)
Raloxifene	0.50	(-0.49, 1.51)	0.04%	12 (6-12)
SSRIs/SNRIs	-0.17	(-0.61, 0.26)	0.01%	8 (4-11)
Isoflavones	-0.48	(-0.82, -0.13)	0.10%	6 (3-9)
Chinese herbal medicine	-0.05	(-0.78, 0.63)	0.09%	9 (4-12)
Black cohosh	-0.92	(-1.8, -0.11)	14.23%	3 (1-9)
Multibotanicals	-0.34	(-1.43, 0.73)	2.88%	7 (1-12)
Acupuncture	-0.54	(-1.49, 0.31)	3.64%	5 (1-11)

Between-study heterogeneity: Standard deviation on the log MRs scale (SD) (95% CrI) 0.50 (0.37, 0.70)

Table 2: Log odd ratios (with their 95% CrI) of all interventions in the network and the probability of being the best treatment for discontinuation of treatment

	Median log odds ratios	95%CrI	Probability of being the best treatment	Median (95% CrI) treatment rank
Placebo	Reference treatment		0.00%	6 (4-8)
Oestrogen + progestogen oral	-0.50	(-0.99, -0.01)	2.83%	3 (1-6)
Conjugated oestrogens plus bazedoxifene	-1.16	(-2.28, 0.002)	37.34%	2 (1-6)
Tibolone	1.73	(-0.06, 5.15)	0.03%	10 (6-10)
SSRIs/SNRIs	0.50	(0.06, 0.96)	0.00%	8 (6-10)
Gabapentin	-0.13	(-0.46, 0.21)	0.08%	5 (3-8)
Isoflavones	-0.05	(-0.67, 0.57)	0.29%	6 (2-9)
Chinese herbal medicine	0.46	(-0.86, 1.9)	0.66%	8 (2-10)
Multibotanicals	-0.70	(-2.63, 1.51)	21.77%	3 (1-10)
Valerian root	-0.91	(-4.41, 1.69)	37.00%	2 (1-10)

Between-study heterogeneity: Standard deviation on the log MRs scale (SD) (95% CrI) 0.25 (0.01, 0.70)